Center-Authored Papers

Filters: Author is Ingle, James N  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y et al..  2013.  Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker.. Journal of the National Cancer Institute. 105(14):1036-1042. Abstract
R
Rugo HS, Rumble BR, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M et al..  2016.  Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(25):3069-103. Abstract
H
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C et al..  2010.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47. Abstract
G
Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S et al..  2016.  Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.. The New England journal of medicine. Abstract
Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM et al..  2014.  Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.. The lancet oncology. 15(4):474-82. Abstract
Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW et al..  2011.  Exemestane for breast-cancer prevention in postmenopausal women.. The New England journal of medicine. 364(25):2381-91. Abstract
D
Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE et al..  2013.  Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(20):5798-807. Abstract